Skip to main content

Table 1 Demographic and clinical characteristics of the study participants at baseline

From: Efficacy and safety of rasagiline in Chinese patients with early Parkinson’s disease: a randomized, double-blind, parallel, placebo-controlled, fixed-dose study

Characteristic Placebo (n = 65) Rasagiline 1 mg (n = 65)
Age (years) 59.5 ± 9.2 58.5 ± 8.7
Female 25 (38.5) 30 (46.2)
BMI (kg/m2) 22.7 ± 3.1 23.7 ± 2.8
Modified HYSS score 1.6 ± 0.5 1.6 ± 0.5
Disease duration (years) 0.11 (0.00, 5.46) 0.10 (0.00, 6.15)
UPDRS score
 Total 28.56 ± 1.93 26.14 ± 1.46
 Part I 1.51 ± 0.20 1.58 ± 0.18
 Part II 7.95 ± 0.58 7.24 ± 0.41
 Part III 19.10 ± 10.60 17.33 ± 8.67
CGI-S score 3.1 ± 0.7 3.2 ± 0.6
MMSE total score 28.5 ± 1.6 28.8 ± 1.6
Patients with concurrent disorders 34 (52.3) 37 (56.9)
  1. Data are mean ± standard deviation, n (%) or median (minimum, maximum). BMI, body mass index; CGI-S, Clinical Global Impressions Scale-Severity; HYSS, Hoehn and Yahr Staging Scale; MMSE, mini mental state examination; UPDRS, Unified Parkinson’s Disease Rating Scale